Literature DB >> 8510229

Antisense phosphorothioate oligodeoxynucleotides targeted to the vpr gene inhibit human immunodeficiency virus type 1 replication in primary human macrophages.

C Balotta1, P Lusso, R Crowley, R C Gallo, G Franchini.   

Abstract

The replication of human immunodeficiency viruses (HIV) in human macrophages is influenced by genetic determinants which have been mapped predominantly to the viral envelope. However, in HIV-2, the vpr gene has also been suggested as an important modulator of viral expression in human macrophages. We synthesized five antisense phosphorothioate oligodeoxynucleotides complementary to the vpr mRNA of HIV-1Ba-L, a highly macrophage-tropic viral strain, and measured their effect on HIV-1Ba-L replication in primary human macrophages. All of the oligodeoxynucleotides displayed some level of non-sequence-specific inhibition of viral replication; however, only the antisense one had an additional effect on viral production in primary macrophages. Of the five antisense oligodeoxynucleotides tested, only one did not show any additional effect on viral production, whereas all the others inhibited viral replication to a similar degree (70 to 100%). Variation in the degree of inhibition was observed by using five different donors of human primary macrophages. The phosphorothioate oligonucleotides, targeted to the initiating methionine of the Vpr protein, had an inhibitory effect at both 20 and 10 microM only when the size was increased from 24 to 27 bases. Thus, HIV-1 replication in human macrophages is modulated by the expression of the vpr gene, and it is conceivable that vpr antisense oligodeoxynucleotides could be used in combination with antisense oligodeoxynucleotides against other HIV-1 regulatory genes to better control viral expression in human macrophages.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8510229      PMCID: PMC237816          DOI: 10.1128/JVI.67.7.4409-4414.1993

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells.

Authors:  D Dedera; W Hu; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

2.  Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions.

Authors:  J Sodroski; W C Goh; C Rosen; A Tartar; D Portetelle; A Burny; W Haseltine
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

3.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

4.  Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy.

Authors:  S Koenig; H E Gendelman; J M Orenstein; M C Dal Canto; G H Pezeshkpour; M Yungbluth; F Janotta; A Aksamit; M A Martin; A S Fauci
Journal:  Science       Date:  1986-09-05       Impact factor: 47.728

5.  Formaldehyde regulation.

Authors:  A Wildavsky; J A Todhunter; W R Havender
Journal:  Science       Date:  1984-05-11       Impact factor: 47.728

6.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

7.  Follicular dendritic cells and virus-like particles in AIDS-related lymphadenopathy.

Authors:  J A Armstrong; R Horne
Journal:  Lancet       Date:  1984-08-18       Impact factor: 79.321

8.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

9.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

10.  Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome.

Authors:  D D Ho; T R Rota; R T Schooley; J C Kaplan; J D Allan; J E Groopman; L Resnick; D Felsenstein; C A Andrews; M S Hirsch
Journal:  N Engl J Med       Date:  1985-12-12       Impact factor: 91.245

View more
  48 in total

Review 1.  Molecular pathways in virus-induced cytokine production.

Authors:  T H Mogensen; S R Paludan
Journal:  Microbiol Mol Biol Rev       Date:  2001-03       Impact factor: 11.056

2.  Impairment of human immunodeficiency virus type 1 (HIV-1) entry into Jurkat T cells by constitutive expression of the HIV-1 vpr protein: role of CD4 down-modulation.

Authors:  L Conti; B Varano; M C Gauzzi; P Matarrese; M Federico; W Malorni; F Belardelli; S Gessani
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Depletion of Wee-1 kinase is necessary for both human immunodeficiency virus type 1 Vpr- and gamma irradiation-induced apoptosis.

Authors:  Huidong Yuan; Yi-Ming Xie; Irvin S Y Chen
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B.

Authors:  F Re; D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.

Authors:  Y L Lu; R P Bennett; J W Wills; R Gorelick; L Ratner
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Modified antisense oligodeoxynucleotides against the splice acceptor site of tat do not inhibit in vitro hematopoietic colony growth in HIV-positive patients.

Authors:  R G Geissler; J Muth; A Maurer; U Mentzel; M Mag; J W Engels; D Hoelzer; A Ganser
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

7.  A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects.

Authors:  I G Macreadie; L A Castelli; D R Hewish; A Kirkpatrick; A C Ward; A A Azad
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

8.  The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.

Authors:  E Kondo; F Mammano; E A Cohen; H G Göttlinger
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles.

Authors:  C Lavallée; X J Yao; A Ladha; H Göttlinger; W A Haseltine; E A Cohen
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Vpr-induced cell cycle arrest is conserved among primate lentiviruses.

Authors:  V Planelles; J B Jowett; Q X Li; Y Xie; B Hahn; I S Chen
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.